Phase I/Ib Clinical Trial of Sabatolimab, an Anti–TIM-3 Antibody, Alone and in Combination with Spartalizumab, an Anti–PD-1 Antibody, in Advanced Solid Tumors

Giuseppe Curigliano, Hans Gelderblom, Nicolas Mach, +16

Clinical Cancer Research

Genomic and Proteomic Profiling Reveals Reduced Mitochondrial Function and Disruption of the Neuromuscular Junction Driving Rat Sarcopenia

Chikwendu Ibebunjo, Joel M. Chick, Tracee Kendall, +19

Molecular and Cellular Biology

MitophagyMuscle FunctionEngineeringSkeletal Muscle MassSarcopenia Distinct +14

Blockade of the Activin Receptor IIB Activates Functional Brown Adipogenesis and Thermogenesis by Inducing Mitochondrial Oxidative Metabolism

Brigitte Fournier, Ben J. Murray, Sabine Gutzwiller, +14

Molecular and Cellular Biology

Metabolic RemodelingRedox BiologyCellular PhysiologyOxidative StressMetabolic Syndrome +18

1,25-DIHYDROXYVITAMIN D₃Induces the expression of vascular endothelial growth factor in osteoblastic cells.

Jean-Marc Schlaeppi, Sabine Gutzwiller, Günter Finkenzeller, +1

Endocrine Research

SclerostinBiomedical EngineeringOsteoporosisRegenerative MedicineBone Disease +16

Blockade of Metallothioneins 1 and 2 Increases Skeletal Muscle Mass and Strength

Serge Summermatter, Anais Bouzan, Eliane Pierrel, +9

Molecular and Cellular Biology

Absence of Estrogen Receptor-Related-α Increases Osteoblastic Differentiation and Cancellous Bone Mineral Density

Isabelle Delhon, Sabine Gutzwiller, Frédéric Morvan, +6

Endocrinology

GynecologyOsteoporosisOrthopaedic SurgeryBone Morphogenic ProteinBone Remodeling +15

Estrogen Receptor (ER)-α, but Not ER-β, Mediates Regulation of the Insulin-like Growth Factor I Gene by Antiestrogens

Brigitte Fournier, Sabine Gutzwiller, Tanja Dittmar, +3

Journal of Biological Chemistry

Estrogen Receptor α (ERα) and Estrogen Related Receptor α (ERRα) are both transcriptional regulators of the Runx2-I isoform

Martial Kammerer, Sabine Gutzwiller, Daniela Stauffer, +3

Molecular and Cellular Endocrinology

Transcriptional RegulationSystems BiologySignal TransductionDevelopmental BiologyEndocrine Mechanism +11

Phase (Ph) II study of MBG453 + spartalizumab in patients (pts) with non-small cell lung cancer (NSCLC) and melanoma pretreated with anti–PD-1/L1 therapy

Nicolas Mach, Giuseppe Curigliano, Armando Santoro, +11

Annals of Oncology

Anti–pd-1/l1 TherapyMedicineImmunologyPathologyImmune Checkpoint Inhibitor +6

Sabatolimab in combination with spartalizumab in patients with non-small cell lung cancer or melanoma who received prior treatment with anti-PD-1/PD-L1 therapy: a phase 2 multicentre study

Chia‐Chi Lin, Giuseppe Curigliano, Armando Santoro, +12

BMJ Open